Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spanish regions look set to overspend health budgets

This article was originally published in Clinica

Executive Summary

Spain's eight autonomous regions have spent 75% of their annual health budgets in the first eight months of the year, reveals Insalud's subdirectorate general of economic expenditure. This compares unfavourably with the national health agency itself, which has slightly underspent for the period. Those regions which have taken control of their own budgets have already spent Pta 1,505,182 million ($11,852 million) of their annual budget of Pta 1,994,363 million, while Insalud-controlled health expenditure was 60% of its annual budget of Pta 1,295,208 million. In the present situation, there is no mechanism to increase budgets during the year.

You may also be interested in...



What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Vildagliptin Prices Fall By Over 70% In India Post Patent Expiry

Vildagliptin formulation prices fall by over 70% following the expiry of a patent held by Novartis in India. The innovator, meanwhile, is cashing in on co-marketing agreements with Indian partners like USV and Cipla

Medtechs Enter The Decade Of Digital, Consumers and Wellness

For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

Topics

UsernamePublicRestriction

Register

MT093529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel